Related Experiment Video
Updated: Aug 3, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Statins in homozygous familial hypercholesterolemia
A D Marais1, D J Blom, J C Firth
1Lipid Clinic and Laboratory, Department of Internal Medicine, University of Cape Town Health Sciences Faculty, Anzio Road, Observatory 7925, South Africa. dmarais@uctgsh1.uct.ac.za
Current Atherosclerosis Reports
|January 5, 2002
Summary
High-dose statins combined with other lipid-modifying strategies are recommended for managing homozygous familial hypercholesterolemia (HFH). This approach offers improved dyslipidemia control for this rare, severe condition.
Area of Science:
- Cardiology
- Genetics
- Pharmacology
Background:
- Homozygous familial hypercholesterolemia (HFH) is a rare genetic disorder causing severe, premature atherosclerosis.
- Traditional treatments like portacaval shunting, plasmapheresis, and liver transplantation have limitations.
- Pharmacologic control is crucial, especially as a bridge to other interventions.
Purpose of the Study:
- To review the current understanding and utility of statins in treating homozygous familial hypercholesterolemia.
- To assess the role of statins in managing severe dyslipidemia associated with HFH.
- To provide recommendations for optimizing lipid-lowering therapy in HFH patients.
Main Methods:
- Review of existing studies and clinical experience with statin therapy in homozygous familial hypercholesterolemia.
- Analysis of the effectiveness of statins as a cholesterol-lowering treatment.
- Evaluation of combination therapy approaches for dyslipidemia management.
Main Results:
- Experience with statins in HFH is limited but growing.
- Statins represent a significant advancement in managing HFH.
- High-dose statins show promise, particularly when used with other lipid-modifying strategies.
Conclusions:
- High-dose statins are recommended for homozygous familial hypercholesterolemia.
- Combination therapy with other lipid-modifying strategies is essential for optimal dyslipidemia control.
- Statins offer a vital pharmacologic option for HFH management.
More Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:18Lipids: Dietary Sources and Requirements
Lipids are an essential component of a balanced human diet. Triglycerides, which make up the majority of dietary lipids, are found in both saturated fats—commonly present in meat, dairy products, and certain tropical plants like coconut, and hydrogenated oils such as margarine and baking shortenings (trans fats)—and unsaturated fats, which are abundant in seeds, nuts, olive oil, and most vegetable oils. The main sources of cholesterol include egg yolks, various meats and organ meats, shellfish,...
01:29Cholesterol: Significance and Regulation
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...